Literature DB >> 14695539

Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency.

Flora Peyvandi1, Liliana Tagliabue, Marzia Menegatti, Mehran Karimi, Istvan Komáromi, Eva Katona, Laszlo Muszbek, Pier Mannuccio Mannucci.   

Abstract

Factor XIII (FXIII) deficiency is a very rare severe autosomal bleeding disorder with a frequency of 1:2,000,000 in the general population and only a few patients have been genetically characterized so far. We report a phenotype-genotype characterization of 10 unrelated Iranian patients. Two FXIII (transglutaminase) activity assays showed no FXIII activity, except a conserved residual activity in patients receiving prophylactic substitution treatment. FXIII antigen concentrations measured by two immunoassays were comparable. Genotype characterization identified four novel mutations (2 missense and 2 small deletions) and two previously reported missense mutations in the FXIII A subunit gene (F13A). Molecular modeling was carried out to reveal the structural consequences of the missense mutations, that caused the replacement of an arginine residue involved in the formation of structurally important extensive hydrogen-bonded network. The replacements [c.320G>A (p.Arg77His) in the beta-sandwich, c.868C>T (p.Arg260Cys), c.869G>A (p.Arg260His) and c.1236G>T (p.Arg382Ser) in the core domain] resulted in the loss or impairment of such H-bonded network. Energy decomposition analysis demonstrated that this situation leads to the instability and perhaps to the incorrect folding of the A subunit, that would explain the development of severe FXIII deficiency. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695539     DOI: 10.1002/humu.9206

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  Identification of a novel mutation combination in factor XIII deficiency: genetic update to the first reported case in the United States.

Authors:  Amy Halverstadt; Sean Walsh; Stephen M Roth; Robert E Ferrell; James M Hagberg
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

2.  Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.

Authors:  Shoko Maeda; Wei Guang Zhang; Masayoshi Souri; Vivien C Yee; Akitada Ichinose
Journal:  J Biochem       Date:  2012-08-25       Impact factor: 3.387

3.  Laboratory Diagnosis of Factor XIII Deficiency in Developing Countries: An Iranian Experience.

Authors:  Akbar Dorgalaleh; Shadi Tabibian; Mahmood Shams; Behnaz Tavasoli; Maryam Gheidishahran; Morteza Shamsizadeh
Journal:  Lab Med       Date:  2016-06-26

4.  Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2.

Authors:  Kiruphagaran Thangaraju; Róbert Király; Máté A Demény; János András Mótyán; Mónika Fuxreiter; László Fésüs
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

5.  Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement.

Authors:  Siyu Ma; Changming Chen; Qian Liang; Xi Wu; Xuefeng Wang; Wenman Wu; Yan Liu; Qiulan Ding
Journal:  Orphanet J Rare Dis       Date:  2019-07-24       Impact factor: 4.123

Review 6.  How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency.

Authors:  Hojat Shahraki; Akbar Dorgalaleh; Majid Fathi; Shadi Tabibian; Shahram Teimourian; Hasan Mollanoori; Alireza Khiabani; Farhad Zaker
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01

Review 7.  Current understanding in diagnosis and management of factor XIII deficiency.

Authors:  M Naderi; A Dorgalaleh; Sh Tabibian; Sh Alizadeh; P Eshghi; Gh Solaimani
Journal:  Iran J Ped Hematol Oncol       Date:  2013-10-22

8.  Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay.

Authors:  Mobin A Karimi; Eric Lee; Michael H Bachmann; Ana Maria Salicioni; Edward M Behrens; Taku Kambayashi; Cynthia L Baldwin
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.